LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025.

LIXTE Biotech is a clinical-stage pharmaceutical company focusing on developing novel cancer therapies by targeting epigenetic modulation. The company's lead compound, LB-100, inhibits protein phosphatase 2A, sensitizing tumors to DNA-damaging agents. Multiple Phase 1B/2 trial readouts are expected in 2H 2025, with preliminary efficacy data for ovarian clear cell carcinoma and advanced soft tissue sarcoma trials, and initial biomarker and response data for metastatic microsatellite stable colon cancer. The global oncology market is projected to reach $200 billion by 2025.